Chaperone-rich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR-ABL positive leukemia

FASEB Journal

Volumn 21, Issue 9, 2007, Pages 2173-2184

  Kislin, Kerri L ^a,c   Marron, Marilyn T ^c   Li, Gang ^c   Graner, Michael W ^b   Katsanis, Emmanuel ^c  

^a UNIVERSITY OF ARIZONA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Anticancer vaccine; Heat shock proteins; Isoelectric focusing; Peptide antigens; T cells

Indexed keywords

BCR ABL PROTEIN; CHAPERONE; GLYCYLPHENYLALANYLLYSYLGLUTAMINYLSERYLSERYLLYSYLALANYLLEUCINE; PEPTIDE DERIVATIVE; SERYLISOLEUCYLISOLEUCYLASPARAGINYLPHENYLALANYLGLUTAMYLLYSYLLEUCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL LYSATE; CONTROLLED STUDY; FEMALE; LEUKEMIA; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; BONE MARROW CELLS; CALCIUM-BINDING PROTEIN, VITAMIN D-DEPENDENT; CANCER VACCINES; CELLS, CULTURED; DENDRITIC CELLS; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; EGG PROTEINS; FEMALE; FUSION PROTEINS, BCR-ABL; HSP72 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; IMMUNOTHERAPY, ACTIVE; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; LIVER; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MOLECULAR CHAPERONES; OLIGOPEPTIDES; OVALBUMIN; TISSUE EXTRACTS;

MURINAE;

EID: 34347408042     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.06-7843com     Document Type: Article

References (58)

1. Gething, M. J., and Sambrook, J. (1992) Protein folding in the cell. Nature 355, 33-45
2. Parsell, D. A., and Lindquist, S. (1993) The function of heat-shock proteins in stress tolerance: degradation and reactivation of damaged proteins. Annu. Rev. Genet. 27, 437-496
3. Feder, M. E., and Hofmann, G. E. (1999) Heat-shock proteins, molecular chaperones, and the stress response: evolutionary and ecological physiology. Annu. Rev. Physiol. 61, 243-282
4. Berwin, B., Hart, J. P., Rice, S., Gass, C., Pizzo, S. V., Post, S. R., and Nicchitta, C. V. (2003) Scavenger receptor-A mediates gp96/GRP94 and calreticulin internalization by antigen-presenting cells. EMBO J. 22, 6127-6136
5. Binder, R. J., Blachere, N. E., and Srivastava, P. K. (2001) Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatibility complex I molecules. J. Biol. Chem. 276, 17163-17171
6. Binder, R. J., and Srivastava, P. K. (2005) Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells. Nat. Immunol. 6, 593-599
7. Li, Z. (1997) Priming of T cells by heat shock protein-peptide complexes as the basis of tumor vaccines. Semin. Immunol. 9, 315-322
8. Nicchitta, C. V. (2003) Re-evaluating the role of heat-shock protein-peptide interactions in tumour immunity. Nat. Rev. Immunol. 3, 427-432
9. Nicchitta, C. V., Carrick, D. M., and Baker-Lepain, J. C. (2004) The messenger and the message: gp96 (GRP94)-peptide interactions in cellular immunity. Cell Stress Chaper. 9, 325-331
10. Park, J. E., Facciponte, J., Chen, X., MacDonald, I., Repasky, E. A., Manjili, M. H., Wang, X. Y., and Subjeck, J. R. (2006) Chaperoning function of stress protein grp170, a member of the hsp70 superfamily, is responsible for its immunoadjuvant activity. Cancer Res. 66, 1161-1168
11. Wang, X. Y., Kazim, L., Repasky, E. A., and Subjeck, J. R. (2001) Characterization of heat shock protein 110 and glucose-regulated protein 170 as cancer vaccines and the effect of fever-range hyperthermia on vaccine activity. J. Immunol. 166, 490-497
12. Wang, X. Y., Manjili, M. H., Park, J., Chen, X., Repasky, E., and Subjeck, J. R. (2004) Development of cancer vaccines using autologous and recombinant high molecular weight stress proteins. Methods 32, 13-20
13. Zeng, Y., Feng, H., Graner, M. W., and Katsanis, E. (2003) Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity. Blood 101, 4485-4491
14. Kunisawa, J., and Shastri, N. (2003) The group II chaperonin TRiC protects proteolytic intermediates from degradation in the MHC class I antigen processing pathway. Mol. Cell 12, 565-576
15. Baker-LePain, J. C., Reed, R. C., and Nicchitta, C. V. (2003) ISO: a critical evaluation of the role of peptides in heat shock/chaperone protein-mediated tumor rejection. Curr. Opin. Immunol. 15, 89-94
16. Baker-LePain, J. C., Sarzotti, M., and Nicchitta, C. V. (2004) Glucose-regulated protein 94/glycoprotein 96 elicits bystander activation of CD4+ T cell Th1 cytokine production in vivo. J. Immunol. 172, 4195-4203
17. Banchereau, J., and Steinman, R. M. (1998) Dendritic cells and the control of immunity. Nature 392, 245-252
18. Baker-LePain, J. C., Sarzotti, M., Fields, T. A., Li, C. Y., and Nicchitta, C. V. (2002) GRP94 (gp96) and GRP94 N-terminal geldanamycin binding domain elicit tissue nonrestricted tumor suppression. J. Exp. Med. 196, 1447-1459
19. Calderwood, S. K., Theriault, J. R., and Gong, J. (2005) How is the immune response affected by hyperthermia and heat shock proteins? Int. J. Hyperthermia. 21, 713-716
20. MacAry, P. A., Javid, B., Floto, R. A., Smith, K. G., Oehlmann, W., Singh, M., and Lehner, P. J. (2004) HSP70 peptide binding mutants separate antigen delivery from dendritic cell stimulation. Immunity 20, 95-106
21. Rosser, M. F., Trotta, B. M., Marshall, M. R., Berwin, B., and Nicchitta, C. V. (2004) Adenosine nucleotides and the regulation of GRP94-client protein interactions. Biochemistry 43, 8835-8845
22. Facciponte, J. G., MacDonald, I. J., Wang, X. Y., Kim, H., Manjili, M. H., and Subjeck, J. R. (2005) Heat shock proteins and scavenger receptors: role in adaptive immune responses. Immunol. Invest. 34, 325-342
23. Becker, T., Hartl, F. U., and Wieland, F. (2002) CD40, an extracellular receptor for binding and uptake of Hsp70-peptide complexes. J. Cell Biol. 158, 1277-1285
24. Delneste, Y., Magistrelli, G., Gauchat, J., Haeuw, J., Aubry, J., Nakamura, K., Kawakami-Honda, N., Goetsch, L., Sawamura, T., Bonnefoy, J., and Jeannin, P. (2002) Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. Immunity 17, 353-362
25. Tsan, M. F., and Gao, B. (2004) Endogenous ligands of Toll-like receptors. J. Leukoc. Biol. 76, 514-519
26. Zeng, Y., Graner, M. W., Thompson, S., Marron, M., and Katsanis, E. (2005) Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells. Blood. 105, 2016-2022
27. Graner, M., Raymond, A., Akporiaye, E., and Katsanis, E. (2000) Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines. Cancer Immunol. Immunother. 49, 476-484
28. Feng, H., Zeng, Y., Graner, M. W., Likhacheva, A., and Katsanis, E. (2003) Exogenous stress proteins enhance the immunogenicity of apoptotic tumor cells and stimulate antitumor immunity. Blood 101, 245-252
29. Mosca, P. J., Clay, T. M., Morse, M. A., and Lyerly, H. K. (2005) Immune monitoring. Cancer Treat. Res. 123, 369-388
30. Speiser, D. E., Pittet, M. J., Rimoldi, D., Guillaume, P., Luescher, I. F., Lienard, D., Lejeune, F., Cerottini, J. C., and Romero, P. (2003) Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells. Semin. Cancer Biol. 13, 461-472
31. He, L., Feng, H., Raymond, A., Kreeger, M., Zeng, Y., Graner, M., Whitesell, L., and Katsanis, E. (2001) Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice. Cancer Immunol. Immunother. 50, 31-40
32. Graner, M. W., Zeng, Y., Feng, H., and Katsanis, E. (2003) Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers. Cancer Immunol. Immunother. 52, 226-234
33. Sanderson, S., and Shastri, N. (1994) LacZ inducible, antigen/MHC-specific T cell hybrids. Int. Immunol. 6, 369-376
34. Shevchenko, A., Wilm, M., Vorm, O., and Mann, M. (1996) Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem. 68, 850-858
35. Yates, J. R., 3rd, Eng, J. K., McCormack, A. L., and Schieltz, D. (1995) Method to correlate tandem mass spectra of modified peptides to amino acid sequences in the protein database. Anal. Chem. 67, 1426-1436
36. Srivastava, P. (2002) Roles of heat-shock proteins in innate and adaptive immunity. Nat. Rev. Immunol. 2, 185-194
37. Wells, A. D., and Malkovsky, M. (2000) Heat shock proteins, tumor immunogenicity and antigen presentation: an integrated view. Immunol. Today. 21, 129-132
38. Li, Z., and Srivastava, P. K. (1993) Tumor rejection antigen gp96/grp94 is an ATPase: implications for protein folding and antigen presentation. EMBO J. 12, 3143-3151
39. Srivastava, P. K., Menoret, A., Basu, S., Binder, R. J., and McQuade, K. L. (1998) Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. Immunity 8, 657-665
40. Oki, Y., and Younes, A. (2004) Heat shock protein-based cancer vaccines. Expert. Rev. Vaccines. 3, 403-411
41. Van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., and Boon, T. (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 1643-1647
42. Van den Eynde, B. J., and van der Bruggen, P. (1997) T cell defined tumor antigens. Curr. Opin. Immunol. 9, 684-693
43. Renkvist, N., Castelli, C., Robbins, P. F., and Parmiani, G. (2001) A listing of human tumor antigens recognized by T cells. Cancer Immunol. Immunother. 50, 3-15
44. Bosch, G. J., Joosten, A. M., Kessler, J. H., Melief, C. J., and Leeksma, O. C. (1996) Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. Blood 88, 3522-3527
45. Nieda, M., Nicol, A., Kikuchi, A., Kashiwase, K., Taylor, K., Suzuki, K., Tadokoro, K., and Juji, T. (1998) Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia. Blood 91, 977-983
46. Yotnda, P., Firat, H., Garcia-Pons, F., Garcia, Z., Gourru, G., Vernant, J. P., Lemonnier, F. A., Leblond, V., and Langlade-Demoyen, P. (1998) Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J. Clin. Invest. 101, 2290-2296
47. Li, Z., Qiao, Y., Liu, B., Laska, E. J., Chakravarthi, P., Kulko, J. M., Bona, R. D., Fang, M., Hegde, U., Moyo, V., Tannenbaum, S. H., Menoret, A., Gaffney, J., Glynn, L., Runowicz, C. D., and Srivastava, P. K. (2005) Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia. Clin. Cancer Res. 11, 4460-4468
48. Blachere, N. E., Li, Z., Chandawarkar, R. Y., Suto, R., Jaikaria, N. S., Basu, S., Udono, H., and Srivastava, P. K. (1997) Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J. Exp. Med. 186, 1315-1322
49. Wearsch, P. A., and Nicchitta, C. V. (1997) Interaction of endoplasmic reticulum chaperone GRP94 with peptide substrates is adenine nucleotide-independent. J. Biol. Chem. 272, 5152-5156
50. Manjili, M. H., Henderson, R., Wang, X. Y., Chen, X., Li, Y., Repasky, E., Kazim, L., and Subjeck, J. R. (2002) Development of a recombinant HSP110-HER-2/neu vaccine using the chaperoning properties of HSP110. Cancer Res. 62, 1737-1742
51. Zeng, Y., Graner, M. W., Feng, H., Li, G., and Katsanis, E. (2004) Imatinib mesylate effectively combines with chaperone-rich cell lysate-loaded dendritic cells to treat bcr-abl+ murine leukemia. Int. J. Cancer 110, 251-259
52. Chen, X., Zeng, Y., Li, G., Larmonier, N., Graner, M. W., and Katsanis, E. (2006) Peritransplantation vaccination with chaperone-rich cell lysate induces antileukemia immunity. Biol. Blood Marrow Transpl. 12, 275-283
53. Yu, J. S., Wheeler, C. J., Zeltzer, P. M., Ying, H., Finger, D. N., Lee, P. K., Yong, W. H., Incardona, F., Thompson, R. C., Riedinger, M. S., Zhang, W., Prins, R. M., and Black, K. L. (2001) Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res. 61, 842-847
54. Indrova, M., Reinis, M., Bubenik, J., Jandlova, T., Bieblova, J., Vonka, V., and Velek, J. (2004) Immunogenicity of dendritic cell-based HPV16 E6/E7 peptide vaccines: CTL activation and protective effects. Folia. Biol. (Praha). 50, 184-193
55. Liau, L. M., Prins, R. M., Kiertscher, S. M., Odesa, S. K., Kremen, T. J., Giovannone, A. J., Lin, J. W., Chute, D. J., Mischel, P. S., Cloughesy, T. F., and Roth, M. D. (2005) Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin. Cancer Res. 11, 5515-5525
56. Horimoto, M., Kato, J., Takimoto, R., Terui, T., Mogi, Y., and Niitsu, Y. (1995) Identification of a transforming growth factor beta-1 activator derived from a human gastric cancer cell line. Br. J. Cancer 72, 676-682
57. Kobie, J. J., Wu, R. S., Kurt, R. A., Lou, S., Adelman, M. K., Whitesell, L. J., Ramanathapuram, L. V., Arteaga, C. L., and Akporiaye, E. T. (2003) Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res. 63, 1860-1864
58. Shah, M., Stanek, J., and Handwerger, S. (1998) Differential localization of heat shock proteins 90, 70, 60 and 27 in human decidua and placenta during pregnancy. Histochem. J. 30, 509-518